A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Ovarian Cancer|Breast Cancer|Prostate Cancer
Interventions: DRUG: LY2606368
Sponsor: National Cancer Institute (NCI)